- Therapeutic Development
- Vaccine Production
- Drug Discovery
- Others
mRNA CDMO Services Market was valued at USD 3,876.4 million in 2023 and is poised to grow at a 7.5% CAGR from 2024 to 2030. mRNA CDMO services provide the production of mRNA sequences based on computer-provided sequences, and custom-tailored services are provided for mRNA template design including UTR and codon optimization. The continuously growing pharmaceutical companies and extensive product launches are major factors for the market growth of mRNA CDMO services. The increasing incidence of cancer patients accelerates the research and development activities which is the major factor that drives the market.
The high impact of COVID-19 boosts vaccine production and outsourcing contract manufacturing organizations raising the overall demand in the market, CDMOs are gaining significant market traction through technological advancement and a specialised workforce, and the extensive demand for CDMOs generates lucrative opportunities in the market. the contract basis development become a major trend in the market extensive production of vaccines and biologicals is the major trend in the CDMO services market. High production costs associated with equipment and workforce hinder the market which become major restraints in the mRNA CDMO services market.
MRNA CDMO Services Market Key Developments:
- In April 2022, Novasep, a Lyon, France-based CDMO of APIs and antibody-drug conjugates, and PharmaZell, a Raubling, Germany-based CDMO of small-molecule APIs get merged this strategic merger to create a technology-driven, leading CDMO and API manufacturer.
- In October 2021, BioCina, a contract development and manufacturing organization (CDMO) specializing in process development and cGMP manufacturing of microbial-based therapeutics and mRNA vaccines announced the full and final transition from Hospira Adelaide Pty. Ltd., an affiliate of Pfizer Inc., of its biologics manufacturing facility, colleagues and operations in Adelaide, Australia. This completes BioCina's August 2020 acquisition of the facility.
mRNA CDMO Services Market Summary
Study Period
2024-2030
Base Year
2023
CAGR
7.5%
Largest Market
North America
Fastest Growing Market
North America
mRNA CDMO Services Market Dynamics
The increasing prevalence of cancer diseases and growing demand for pharmaceutical products across the world are the major market drivers in the mRNA CDMO Services Market during the forecast period. Contract Development and Manufacturing Organization (CDMO) become a fragmented market, resulting in a higher demand for pharmaceuticals market for rapid innovations to develop effective process solutions that enhance the drug development process, additionally, the rise in the incidence of genetic disorders increased the services market which is the major factor for the growth. Hence, this will drive the global market growth at a significant rate.
Asia-Pacific Got Significant Share Of
mRNA CDMO Services Market Regional Analysis
The mRNA CDMO Services Market in the Asia Pacific hold a significant revenue share in 2022, and, in the following years, it is predicted to increase rapidly. It is attributed to the increasing number of diseases that need a large range of generic drugs, high uptake of small molecule drugs across a wide range of diseases, patent expiration of various drugs and accelerated demand for active pharmaceutical ingredients (APIs) require standard CDMOs in the region. China, India, and Japan are growing at a significant rate, and increased research and development activities accelerate the market in the forecast years. North America holds the major market share in the global market and is expected to dominate the market due to the presence of global key players privatization of clinical trials, and outsourcing of pharmaceuticals ingredients regulate the market.
Latin America
Europe
Asia Pacific
Middle East
North America
Key Features of the Reports
- The report provides granular level information about the market size, regional market share, historic market (2019-2023), and forecast (2024-2030)
- The report covers in-detail insights about the competitor’s overview, company share analysis, key market developments, and key strategies.
- The report outlines drivers, restraints, unmet needs, and trends that are currently affecting the market.
- The report tracks recent innovations, key developments, and start-up details that are actively working in the market.
- The report provides a plethora of information about market entry strategies, regulatory framework, and reimbursement scenario.
mRNA CDMO Services Market Segmentation
By Application
By End User
- Biopharmaceuticals Companies
- Contract Research Organizations
- Others
By Geography
- Asia Pacific
- Europe
- North America
- Latin America
- MEA
Frequently Asked Questions
The mRNA CDMO services market size was valued at USD 3,876.4 million in 2022, growing at a 7.5% CAGR from 2023 to 2029.
The leading players in the mRNA CDMO Services Market are Eurofins Scientific, WuXi Biologics, Samsung Biologics, Catalent, Inc., Rentschler Biopharma SE, AGC Biologics, BioCina, Novasep, Recipharm AB, Siegfried Holding AG, Boehringer Ingelheim, and FUJIFILM Diosynth Biotechnologies
Historic years considered for the market study are 2019 through 2023, 2023 is considered as the base year for market estimation and the forecast presented from 2024 to 2030.
| 1.Executive Summary |
| 2.Global mRNA CDMO Services Market Introduction |
| 2.1.Global mRNA CDMO Services Market - Taxonomy |
| 2.2.Global mRNA CDMO Services Market - Definitions |
| 2.2.1. By Application |
| 2.2.2. By End User |
| 2.2.3. By Region |
| 3.Global mRNA CDMO Services Market Dynamics |
| 3.1. Drivers |
| 3.2. Restraints |
| 3.3. Opportunities/Unmet Needs of the Market |
| 3.4. Trends |
| 3.5. Product Landscape |
| 3.6. New Product Launches |
| 3.7. Impact of COVID 19 on Market |
| 4.Global mRNA CDMO Services Market Analysis, 2019 - 2023 and Forecast 2024 - 2030 |
| 4.1. Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030, (Sales Value USD Million) |
| 4.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) |
| 4.3. Market Opportunity Analysis |
| 5.Global mRNA CDMO Services Market By Application, 2019 - 2023 and Forecast 2024 - 2030 (Sales Value USD Million) |
| 5.1. Therapeutic Development |
| 5.1.1. Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030, (Sales Value USD Million) |
| 5.1.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
| 5.1.3. Market Opportunity Analysis |
| 5.2. Vaccine Production |
| 5.2.1. Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030, (Sales Value USD Million) |
| 5.2.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
| 5.2.3. Market Opportunity Analysis |
| 5.3. Drug Discovery |
| 5.3.1. Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030, (Sales Value USD Million) |
| 5.3.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
| 5.3.3. Market Opportunity Analysis |
| 5.4. Others |
| 5.4.1. Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030, (Sales Value USD Million) |
| 5.4.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
| 5.4.3. Market Opportunity Analysis |
| 6.Global mRNA CDMO Services Market By End User, 2019 - 2023 and Forecast 2024 - 2030 (Sales Value USD Million) |
| 6.1. Biopharmaceuticals Companies |
| 6.1.1. Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030, (Sales Value USD Million) |
| 6.1.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
| 6.1.3. Market Opportunity Analysis |
| 6.2. Contract Research Organizations |
| 6.2.1. Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030, (Sales Value USD Million) |
| 6.2.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
| 6.2.3. Market Opportunity Analysis |
| 6.3. Others |
| 6.3.1. Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030, (Sales Value USD Million) |
| 6.3.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
| 6.3.3. Market Opportunity Analysis |
| 7.Global mRNA CDMO Services Market By Region, 2019 - 2023 and Forecast 2024 - 2030 (Sales Value USD Million) |
| 7.1. North America |
| 7.1.1. Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030, (Sales Value USD Million) |
| 7.1.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
| 7.1.3. Market Opportunity Analysis |
| 7.2. Europe |
| 7.2.1. Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030, (Sales Value USD Million) |
| 7.2.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
| 7.2.3. Market Opportunity Analysis |
| 7.3. Asia Pacific (APAC) |
| 7.3.1. Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030, (Sales Value USD Million) |
| 7.3.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
| 7.3.3. Market Opportunity Analysis |
| 7.4. Middle East and Africa (MEA) |
| 7.4.1. Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030, (Sales Value USD Million) |
| 7.4.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
| 7.4.3. Market Opportunity Analysis |
| 7.5. Latin America |
| 7.5.1. Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030, (Sales Value USD Million) |
| 7.5.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
| 7.5.3. Market Opportunity Analysis |
| 8.North America mRNA CDMO Services Market ,2019 - 2023 and Forecast 2024 - 2030 (Sales Value USD Million) |
| 8.1. Application Analysis 2019 - 2023 and Forecast 2024 - 2030 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
| 8.1.1.Therapeutic Development |
| 8.1.2.Vaccine Production |
| 8.1.3.Drug Discovery |
| 8.1.4.Others |
| 8.2. End User Analysis 2019 - 2023 and Forecast 2024 - 2030 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
| 8.2.1.Biopharmaceuticals Companies |
| 8.2.2.Contract Research Organizations |
| 8.2.3.Others |
| 8.3. Country Analysis 2019 - 2023 and Forecast 2024 - 2030 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
| 8.3.1.United States of America (USA) |
| 8.3.2.Canada |
| 9.Europe mRNA CDMO Services Market ,2019 - 2023 and Forecast 2024 - 2030 (Sales Value USD Million) |
| 9.1. Application Analysis and Forecast by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
| 9.1.1.Therapeutic Development |
| 9.1.2.Vaccine Production |
| 9.1.3.Drug Discovery |
| 9.1.4.Others |
| 9.2. End User Analysis 2019 - 2023 and Forecast 2024 - 2030 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
| 9.2.1.Biopharmaceuticals Companies |
| 9.2.2.Contract Research Organizations |
| 9.2.3.Others |
| 9.3. Country Analysis 2019 - 2023 and Forecast 2024 - 2030 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
| 9.3.1.Germany |
| 9.3.2.France |
| 9.3.3.Italy |
| 9.3.4.United Kingdom (UK) |
| 9.3.5.Spain |
| 10.Asia Pacific (APAC) mRNA CDMO Services Market ,2019 - 2023 and Forecast 2024 - 2030 (Sales Value USD Million) |
| 10.1. Application Analysis and Forecast by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
| 10.1.1.Therapeutic Development |
| 10.1.2.Vaccine Production |
| 10.1.3.Drug Discovery |
| 10.1.4.Others |
| 10.2. End User Analysis 2019 - 2023 and Forecast 2024 - 2030 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
| 10.2.1.Biopharmaceuticals Companies |
| 10.2.2.Contract Research Organizations |
| 10.2.3.Others |
| 10.3. Country Analysis 2019 - 2023 and Forecast 2024 - 2030 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
| 10.3.1.China |
| 10.3.2.India |
| 10.3.3.Australia and New Zealand (ANZ) |
| 10.3.4.Japan |
| 10.3.5.Rest of APAC |
| 11.Middle East and Africa (MEA) mRNA CDMO Services Market ,2019 - 2023 and Forecast 2024 - 2030 (Sales Value USD Million) |
| 11.1. Application Analysis and Forecast by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
| 11.1.1.Therapeutic Development |
| 11.1.2.Vaccine Production |
| 11.1.3.Drug Discovery |
| 11.1.4.Others |
| 11.2. End User Analysis 2019 - 2023 and Forecast 2024 - 2030 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
| 11.2.1.Biopharmaceuticals Companies |
| 11.2.2.Contract Research Organizations |
| 11.2.3.Others |
| 11.3. Country Analysis 2019 - 2023 and Forecast 2024 - 2030 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
| 11.3.1.GCC Countries |
| 11.3.2.South Africa |
| 11.3.3.Rest of MEA |
| 12.Latin America mRNA CDMO Services Market ,2019 - 2023 and Forecast 2024 - 2030 (Sales Value USD Million) |
| 12.1. Application Analysis and Forecast by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
| 12.1.1.Therapeutic Development |
| 12.1.2.Vaccine Production |
| 12.1.3.Drug Discovery |
| 12.1.4.Others |
| 12.2. End User Analysis 2019 - 2023 and Forecast 2024 - 2030 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
| 12.2.1.Biopharmaceuticals Companies |
| 12.2.2.Contract Research Organizations |
| 12.2.3.Others |
| 12.3. Country Analysis 2019 - 2023 and Forecast 2024 - 2030 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
| 12.3.1.Brazil |
| 12.3.2.Mexico |
| 12.3.3.Rest of LA |
| 13. Competition Landscape |
| 13.1. Market Player Profiles (Introduction, Brand/Product Sales, Financial Analysis, Product Offerings, Key Developments, Collaborations, M & A, Strategies, and SWOT Analysis) |
| 13.2.1.Eurofins Scientific |
| 13.2.2.WuXi Biologics |
| 13.2.3.Samsung Biologics |
| 13.2.4.Catalent, Inc. |
| 13.2.5.Rentschler Biopharma SE |
| 13.2.6.AGC Biologics |
| 13.2.7.Novasep |
| 13.2.8.BioCina |
| 13.2.9.Recipharm AB |
| 13.2.10.Siegfried Holding AG |
| 13.2.11.Boehringer Ingelheim |
| 13.2.12.FUJIFILM Diosynth Biotechnologies |
| 14. Research Methodology |
| 15. Appendix and Abbreviations |
- Eurofins Scientific
- WuXi Biologics
- Samsung Biologics
- Catalent, Inc.
- Rentschler Biopharma SE
- AGC Biologics
- Novasep
- BioCina
- Recipharm AB
- Siegfried Holding AG
- Boehringer Ingelheim
- FUJIFILM Diosynth Biotechnologies